Nivolumab Plus Chemotherapy Continues to Demonstrate Long-Term Survival Benefits in Patients with Gastric, GEJ and Oesophageal Adenocarcinoma By Ogkologos - February 24, 2026 313 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from 5 years of follow-up of CheckMate 649 study Source RELATED ARTICLESMORE FROM AUTHOR Comprehensive Genomic Profiling with Subsequent Molecularly Guided Therapy Improves Outcomes Over Platinum-based Chemotherapy in Previously Untreated, Unfavourable CUP NCI and CRUK Take on Cancer’s Toughest Problems Tebentafusp Continues to Provide Long-Term OS Benefit in Previously Untreated Patients with Unresectable or Metastatic Uveal Melanoma MOST POPULAR ESMO Calls for Cancer to Be at the Core of the... June 10, 2025 Aiming to Prevent Cancer Cases, ESMO Calls Against Misleading Alcohol-Labelling Following... December 3, 2025 Keanu Reeves Has A Long History Of Supporting Cancer Research January 13, 2022 Activity and Safety of Atezolizumab Combined with Carboplatin and Pemetrexed in... August 30, 2023 Load more HOT NEWS Acalabrutinib-Venetoclax With or Without Obinutuzumab Significantly Prolongs PFS in Fit Patients... ESMO Calls for Cancer to Be at the Core of the... Two Drugs Work Together to Block ‘Master Regulator’ of Breast, Other... What is Mindfulness?
